newsfilter
← Latest News
PR Newswire·

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

ANEB-001 statistically significantly reduced VAS Feeling High in all cohorts (p=<0.0001 at the 30 mg THC dose level)A single 10 mg oral dose of ANEB-001 reduced key symptoms of Accute Cannabinoid Intoxication induced